Evidence map›Paper›PMID 35391882›Full record

ArticleFrontiers in medicine2022

Controversial Flow Cytometry Monitoring of a Relapse Case of Pediatric T Cell Acute Lymphoblastic Leukemia: A Case Report.

Delia Codruţa Popa, Andreea Şerbănică, Radu Obrisca, Ionut Şerbănică, Letiţia Radu, Cristina Jercan, Andra Marcu, Ana Bica, Minodora Asan, Mădălina Petran and 8 more

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 96% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 2 institutions in 1 country.

Delia Codruţa PopaDepartment of Medicine, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.
Andreea ŞerbănicăDepartment of Medicine, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.
Radu ObriscaDepartment of Medicine, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.
Ionut ŞerbănicăDepartment of Medicine, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.
Letiţia RaduDepartment of Medicine, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.
Cristina JercanDepartment of Medicine, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.
Andra MarcuDepartment of Medicine, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.
Ana BicaDepartment of Hematology, Fundeni Clinical Institute, Bucharest, Romania.
Minodora AsanDepartment of Hematology, Fundeni Clinical Institute, Bucharest, Romania.
Mădălina PetranDepartment of Medicine, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.
Mihaela DragomirDepartment of Hematology, Fundeni Clinical Institute, Bucharest, Romania.
Cerasela JardanDepartment of Medicine, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.
Valeria ŢicăDepartment of Hematology, Fundeni Clinical Institute, Bucharest, Romania.
Anca GheorgheDepartment of Hematology, Fundeni Clinical Institute, Bucharest, Romania.
Irina StoianDepartment of Medicine, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.
Daniel CoriuDepartment of Medicine, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.
Anca ColiţăDepartment of Medicine, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.
Andrei ColiţăDepartment of Medicine, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.
Institutul Clinic Fundeni · ROCarol Davila University of Medicine and Pharmacy · RO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acute lymphoblastic leukemia (ALL) is the most frequent childhood cancer, with 80-85% represented by B cell ALL and only 15% by T cell ALL. T Cell ALL (T-ALL) carries a more reserved prognosis compared to B Cell ALL (B-ALL) with regard to response to treatment, risk of relapse, and overall survival. Progress made in current monitoring protocols such as

Indexed as

allotransplantchildrenleukemiarelapsestem cellT cell

Identifiers

PMID35391882
PMCPMC8982560
OpenAlexW4220904289

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.